Authors

Opinion: Fellow Physicians, Please Stop Devaluing Your Medical License

A family medicine physician asks fellow doctors to keep operating to the highest extent of their ability and to remind themselves of the value of their license.

Can C-reactive protein levels predict risk of hypertension in a younger population?

Is hypertension an inflammatory disease?

The Psychology of Money

Anomalous origin of the left anterior descending artery from a separate ostium of the right sinus of Valsalva with abnormal stress test

A 67-year-old man with positive results on a stress myocardial perfusion test was found to have isolated anomalous origin of the left anterior descending coronary artery from a separate coronary ostium of the right sinus of Valsalva. This anomalous artery was not stenotic and coursed over the anterior free wall of the right ventricle, in front of the pulmonary artery. It did not appear to have an intra-arterial or intramyocardial course.

The Newest Addition to the Pain Management Arsenal: Targiniq ER

Abuse-deterrent properties, identical efficacy for pain relief, reversal of opioid-induced constipation, and theoretical tolerance mitigation may give Targiniq ER an interesting advantage over other oral opioids.

The HDL-C Conundrum: When More of the "Good" Isn't So Great

Ethnic differences in blood pressure control

The article by Rehman and colleagues (page 27) offers two important observations about the control of hypertension in African American men.

Late mortality with sirolimus-eluting stents in diseased saphenous vein grafts

In a secondary post-hoc analysis of the Reduction of Restenosis in Saphenous Vein Grafts with Cypher (RRISC) trial, we compared the long-term safety of sirolimus-eluting stents (SES) with bare-metal stents (BMS) in diseased saphenous vein grafts

Second round of gefitinib shows promise in non-small cell lung cancer

Gefitinib, an epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a treatment for non–small cell lung cancer (NSCLC).

Novel First-Line Therapy for Advanced Breast Cancer Buoys Physicians' Hopes